Literature DB >> 27264866

Old and new applications of non-anticoagulant heparin.

Giuseppe Cassinelli1, Annamaria Naggi2.   

Abstract

The aim of this chapter is to provide an overview of non-anticoagulant effects of heparins and their potential use in new therapeutic applications. Heparin and heparin derivatives have been tested in inflammatory, pulmonary and reproductive diseases, in cardiovascular, nephro- and neuro-tissue protection and repair, but also as agents against angiogenesis, atheroschlerosis, metastasis, protozoa and viruses. Targeting and inhibition of specific mediators involved in the inflammatory process, promoting some of the above mentioned pathologies, are reported along with recent studies of heparin conjugates and oral delivery systems. Some reports from the institute of the authors, such as those devoted to glycol-split heparins are also included. Among the members and derivatives of this class, several are undergoing clinical trials as antimetastatic and antimalarial agents and for the treatment of labour pain and severe hereditary anaemia. Other heparins, whose therapeutic targets are non-anticoagulant such as nephropathies, retinopathies and cystic fibrosis are also under investigation.
© 2016 Elsevier Ireland Ltd.

Entities:  

Keywords:  Cancer; Heparins; Inflammation; Neuroprotection; Non-anticoagulant

Mesh:

Substances:

Year:  2016        PMID: 27264866     DOI: 10.1016/S0167-5273(16)12004-2

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  24 in total

1.  Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies.

Authors:  Seungwon An; Ilangovan Raju; Bayasgalan Surenkhuu; Ji-Eun Kwon; Shilpa Gulati; Muge Karaman; Anubhav Pradeep; Satyabrata Sinha; Christine Mun; Sandeep Jain
Journal:  Ocul Surf       Date:  2019-04-06       Impact factor: 5.033

Review 2.  Bioinspired Shielding Strategies for Nanoparticle Drug Delivery Applications.

Authors:  Neetu M Gulati; Phoebe L Stewart; Nicole F Steinmetz
Journal:  Mol Pharm       Date:  2018-05-15       Impact factor: 4.939

3.  Reduced Ischemic Lesion Growth with Heparin in Acute Ischemic Stroke.

Authors:  Eva A Rocha; Ruijun Ji; Hakan Ay; Zixiao Li; Ethem Murat Arsava; Gisele S Silva; Alma Gregory Sorensen; Ona Wu; Aneesh B Singhal
Journal:  J Stroke Cerebrovasc Dis       Date:  2019-03-29       Impact factor: 2.136

4.  Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins.

Authors:  Amy K L Chui; Tilini N Gunatillake; Vera Ignjatovic; Paul T Monagle; Padma Murthi; Shaun P Brennecke; John M Whitelock; Joanne M Said
Journal:  Blood Adv       Date:  2017-07-03

5.  Parasite histones are toxic to brain endothelium and link blood barrier breakdown and thrombosis in cerebral malaria.

Authors:  Christopher A Moxon; Yasir Alhamdi; Janet Storm; Julien M H Toh; Dagmara McGuinness; Joo Yeon Ko; George Murphy; Steven Lane; Terrie E Taylor; Karl B Seydel; Sam Kampondeni; Michael Potchen; James S O'Donnell; Niamh O'Regan; Guozheng Wang; Guillermo García-Cardeña; Malcolm Molyneux; Alister G Craig; Simon T Abrams; Cheng-Hock Toh
Journal:  Blood Adv       Date:  2020-07-14

6.  Osteogenic and Angiogenic Properties of Heparin as a System for Delivery of Biomolecules for Bone Bioengineering: a Brief Critical Review.

Authors:  L S Litvinova; K A Yurova; O G Khaziakhmatova; M Yu Khlusova; V V Malashchenko; E O Shunkin; N M Todosenko; I K Norkin; P A Ivanov; I A Khlusov
Journal:  Biochem Mosc Suppl B Biomed Chem       Date:  2021-05-14

Review 7.  Drug delivery carriers with therapeutic functions.

Authors:  Shuting S Cai; Tianyu Li; Tolulope Akinade; Yuefei Zhu; Kam W Leong
Journal:  Adv Drug Deliv Rev       Date:  2021-07-21       Impact factor: 17.873

8.  Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study.

Authors:  Garyphallia Poulakou; Evangelos Dimakakos; Anastasios Kollias; Konstantinos G Kyriakoulis; Vasiliki Rapti; Ioannis Trontzas; Charalampos Thanos; Mahmoud Abdelrasoul; Theodora Vantana; Konstantinos Leontis; Eleni Kakalou; Katerina Argyraki; Ioannis Baraboutis; Evangelos Michelakis; Evangelos Giamarellos-Bourboulis; Katerina Dimakou; Georgios Tsoukalas; Angeliki Rapti; Evangelos D Michelakis; Konstantinos N Syrigos
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.406

9.  Hemolysis During Pediatric Extracorporeal Membrane Oxygenation: Associations With Circuitry, Complications, and Mortality.

Authors:  Heidi J Dalton; Katherine Cashen; Ron W Reeder; Robert A Berg; Thomas P Shanley; Christopher J L Newth; Murray M Pollack; David Wessel; Joseph Carcillo; Rick Harrison; J Michael Dean; Kathleen L Meert
Journal:  Pediatr Crit Care Med       Date:  2018-11       Impact factor: 3.624

10.  Synthesis and Cell Growth Inhibitory Activity of Six Non-glycosaminoglycan-Type Heparin-Analogue Trisaccharides.

Authors:  Erika Lisztes; Erika Mező; Fruzsina Demeter; Lilla Horváth; Szilvia Bősze; Balázs István Tóth; Anikó Borbás; Mihály Herczeg
Journal:  ChemMedChem       Date:  2021-02-12       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.